The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 29, 2015
Filed:
Oct. 26, 2011
Shelley Sims Belouski, Camarillo, CA (US);
Sirid-aimée Kellerman, Menlo Park, CA (US);
Michael Aidan North, Rancho Santa Fe, CA (US);
Karin Kristina Amundson, San Diego, CA (US);
Vahe Bedian, Framingham, MA (US);
Dana Dan Hu-lowe, Encinitas, CA (US);
Xin Jiang, San Diego, CA (US);
Shannon Marie Karlicek, San Diego, CA (US);
James Arthur Thomson, San Diego, CA (US);
Jianying Wang, San Diego, CA (US);
Grant Raymond Wickman, San Diego, CA (US);
Jingchuan Zhang, Boulder, CO (US);
Shelley Sims Belouski, Camarillo, CA (US);
Sirid-Aimée Kellerman, Menlo Park, CA (US);
Michael Aidan North, Rancho Santa Fe, CA (US);
Karin Kristina Amundson, San Diego, CA (US);
Vahe Bedian, Framingham, MA (US);
Dana Dan Hu-Lowe, Encinitas, CA (US);
Xin Jiang, San Diego, CA (US);
Shannon Marie Karlicek, San Diego, CA (US);
James Arthur Thomson, San Diego, CA (US);
Jianying Wang, San Diego, CA (US);
Grant Raymond Wickman, San Diego, CA (US);
Jingchuan Zhang, Boulder, CO (US);
Pfizer Inc., New York, NY (US);
Amgen Fremont Inc., Fremont, CA (US);
Abstract
The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like, kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.